Zuclopenthixol decanoate administration

Zuclopenthixol has no mutagenic or carcinogenic potential. In a rat oncogenecity study 30 mg/kg/day for two years (top dosage) resulted in slight non-statistical increases in the incidence of mammary adenocarcinomas, pancreatic islet cell adenomas, carcinomas in females and thyroid parafollicular carcinomas. The slight increase in the incidence of these tumors is a common finding for D 2 antagonists, which increase prolactin secretion when administered to rats. The physiological differences between rats and humans with regard to prolactin make the clinical significance of these findings unclear, but it is accepted as not predicting an oncogenic risk in patients.

Zuclopenthixol decanoate administration

zuclopenthixol decanoate administration

Media:

zuclopenthixol decanoate administrationzuclopenthixol decanoate administrationzuclopenthixol decanoate administrationzuclopenthixol decanoate administrationzuclopenthixol decanoate administration

http://buy-steroids.org